87562761MMY1001
Multiple myeloma
A Phase 1, first-in-human study of JNJ-87562761
in relapsed or refractory MM
Phase
Compound
JNJ-87562761
NCT identifier
NCT06604715
Enrollment
N=~80
For more information, including
contact details, please visit
the J&J Clinical Trial Finder
contact details, please visit
the J&J Clinical Trial Finder
Study overview & design
Key eligibility criteria*:
- Relapsed or refractory MM with measurable disease
- Prior therapy including a PI, IMiD, and anti-CD38 therapy
- ECOG PS 0 or 1
- No CNS or meningeal involvement
Study
design
Primary outcomes:
Part 1
- DLTs
Parts 1 and 2
- AEs
Part 2
- Clinically significant abnormal laboratory values
Secondary outcomes:
- Serum concentration of JNJ-87562761
- PK
- ADAs to JNJ-87562761
- ≥PR
- ≥VGPR
- ≥CR
- sCR
- TTR
- DOR
*Not a complete list of inclusion and exclusion criteria.
ADA, antidrug antibody; AE, adverse event; CD, cluster of differentiation; CNS, central nervous system; CR, complete response; DLT, dose-limiting toxicity; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; IMiD, immunomodulatory drug; MM, multiple myeloma; PI, proteasome inhibitor, PK, pharmacokinetics; PR, partial response; sCR, stringent complete response; TTR, time to response; VGPR, very good partial response.